{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:41:15Z","timestamp":1759405275140,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHS-N272201400053C","HHSN272200800039C","U01-AI061142"],"award-info":[{"award-number":["HHS-N272201400053C","HHSN272200800039C","U01-AI061142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.06.043","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:28:17Z","timestamp":1655857697000},"page":"4625-4634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates"],"prefix":"10.1016","volume":"40","author":[{"given":"Yoshikazu","family":"Honda-Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Cartee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Thanawastien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae","family":"Seung Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Killeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2022.06.043_b0005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3855\/jidc.1967","article-title":"Epidemiology, clinical presentation, and patterns of drug resistance of Salmonella Typhi in Karachi","volume":"6","author":"Khan","year":"2012","journal-title":"Pakistan J Infect Dev Ctries"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.043_b0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.043_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MOG.0000000000000406","article-title":"The evolution of antimicrobial resistance in Salmonella Typhi","volume":"34","author":"Karkey","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.vaccine.2022.06.043_b0020","first-page":"1029","article-title":"Use of vaccines for the prevention of typhoid fever","volume":"40","author":"Levine","year":"2003","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.vaccine.2022.06.043_b0025","first-page":"35","article-title":"Development of immune response during typhoid fever in man","volume":"28","author":"Sarma","year":"1977","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.06.043_b0030","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.043_b0035","doi-asserted-by":"crossref","first-page":"e0004926","DOI":"10.1371\/journal.pntd.0004926","article-title":"Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a","volume":"10","author":"Darton","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.043_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Sur","year":"2009","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.vaccine.2022.06.043_b0045","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1016\/j.vaccine.2012.06.015","article-title":"Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi","volume":"30","author":"Khan","year":"2012","journal-title":"Pakistan Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.043_b0050","doi-asserted-by":"crossref","unstructured":"Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2014:CD001261.","DOI":"10.1002\/14651858.CD001261.pub3"},{"key":"10.1016\/j.vaccine.2022.06.043_b0055","doi-asserted-by":"crossref","unstructured":"Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;5:CD001261.","DOI":"10.1002\/14651858.CD001261.pub4"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.043_b0060","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1080\/21645515.2019.1599674","article-title":"In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate","volume":"15","author":"Griffin","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.043_b0065","doi-asserted-by":"crossref","first-page":"e0007912","DOI":"10.1371\/journal.pntd.0007912","article-title":"A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever","volume":"14","author":"Cartee","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.043_b0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0008-8749(86)90221-2","article-title":"Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens","volume":"99","author":"Flebbe","year":"1986","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.043_b0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/CVI.00807-13","article-title":"Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults","volume":"21","author":"Pauksens","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.043_b0080","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/glycob\/cwt053","article-title":"The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions","volume":"23","author":"Cooper","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2022.06.043_b0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/glycob\/cwq201","article-title":"Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 -> 1] poly(fructo-furanosyl) alpha-D-glucose polymers","volume":"21","author":"Cooper","year":"2011","journal-title":"Glycobiology"},{"issue":"44","key":"10.1016\/j.vaccine.2022.06.043_b0090","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2022.06.043_b0095","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2022.06.043_b0100","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1016\/j.vaccine.2021.07.037","article-title":"A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization","volume":"39","author":"Sakala","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.043_b0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/pathogens10050500","article-title":"Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines","volume":"10","author":"Honda-Okubo","year":"2021","journal-title":"Pathogens"},{"issue":"14","key":"10.1016\/j.vaccine.2022.06.043_b0110","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.vaccine.2021.02.041","article-title":"Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity","volume":"39","author":"Quan","year":"2021","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2022.06.043_b0115","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1016\/j.vaccine.2020.10.065","article-title":"Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity","volume":"38","author":"Eichinger","year":"2020","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2022.06.043_b0120","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2020.05.009","article-title":"Adjuvant selection impacts the correlates of vaccine protection against Ebola infection","volume":"38","author":"Stronsky","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.043_b0125","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","article-title":"Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection","volume":"7","author":"Counoupas","year":"2017","journal-title":"Sci Rep"},{"issue":"33","key":"10.1016\/j.vaccine.2022.06.043_b0130","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","article-title":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax delta inulin adjuvant","volume":"34","author":"Gordon","year":"2016","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2022.06.043_b0135","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.043_b0140","doi-asserted-by":"crossref","unstructured":"Heddle R, Smith A, Woodman R, Hissaria P, Petrovsky N. Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy. J Allergy Clin Immunol. 2019;144:504-13 e16.","DOI":"10.1016\/j.jaci.2019.03.035"},{"key":"10.1016\/j.vaccine.2022.06.043_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen(R), an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2022.06.043_b0150","unstructured":"Kruisbeek AM. In vivo depletion of CD4- and CD8-specific T cells. Curr Protoc Immunol. 2001;Chapter 4:Unit 4 1."},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.043_b0155","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.043_b0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.micpath.2016.05.013","article-title":"Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method","volume":"97","author":"Jang","year":"2016","journal-title":"Microb Pathog"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.043_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/infdis\/155.1.79","article-title":"B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity","volume":"155","author":"Clemens","year":"1987","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.043_b0170","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.043_b0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.vaccine.2011.12.046","article-title":"Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine","volume":"30","author":"An","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.043_b0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.043_b0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0264-410X(94)90194-5","article-title":"Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines","volume":"12","author":"Keitel","year":"1994","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.06.043_b0190","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.vaccine.2014.02.050","article-title":"Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children","volume":"32","author":"Szu","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.043_b0195","doi-asserted-by":"crossref","first-page":"e0008171","DOI":"10.1371\/journal.pntd.0008171","article-title":"Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)","volume":"14","author":"Lee","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.043_b0200","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14760584.2017.1374861","article-title":"Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines","volume":"16","author":"Zuckerman","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"26","key":"10.1016\/j.vaccine.2022.06.043_b0205","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.043_b0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.043_b0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mimet.2007.08.009","article-title":"A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses","volume":"71","author":"Yang","year":"2007","journal-title":"J Microbiol Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.043_b0220","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/CVI.00245-09","article-title":"Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu","volume":"16","author":"Pulickal","year":"2009","journal-title":"Nepal Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.06.043_b0225","article-title":"Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model","volume":"8","author":"Juel","year":"2017","journal-title":"Front Immunol"},{"issue":"10111","key":"10.1016\/j.vaccine.2022.06.043_b0230","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/S0140-6736(17)32407-8","article-title":"Typhoid vaccine development with a human challenge model","volume":"390","author":"Feasey","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.06.043_b0235","first-page":"53","article-title":"Systemic and intestinal immunities after different typhoid vaccinations","volume":"5","author":"Sarasombath","year":"1987","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.vaccine.2022.06.043_b0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0952-7915(95)80109-X","article-title":"T cell independent antigens","volume":"7","author":"Mond","year":"1995","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.043_b0245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2009.06.003","article-title":"IgM in microbial infections: taken for granted?","volume":"125","author":"Racine","year":"2009","journal-title":"Immunol Lett"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.043_b0250","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/CVI.00289-13","article-title":"Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States","volume":"20","author":"Trebicka","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.043_b0255","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI33998","article-title":"The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children","volume":"118","author":"MacLennan","year":"2008","journal-title":"J Clin Invest"},{"issue":"36","key":"10.1016\/j.vaccine.2022.06.043_b0260","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.043_b0265","doi-asserted-by":"crossref","first-page":"e0132003","DOI":"10.1371\/journal.pone.0132003","article-title":"Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200809X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200809X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:50Z","timestamp":1759403810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200809X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":53,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X2200809X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}